Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

3.2K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
3.2K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

2.3K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.3K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

1.1K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.1K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

7.2K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.2K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient knowledge, home care practices, and peri-implant disease: a preliminary survey analysis of awareness gaps and cleaning behaviors.

Frontiers in oral health·2026
Same author

Targeting Mu opioid receptor neurons of the habenula to limit naloxone aversion.

Biological psychiatry·2026
Same author

Oral wound healing in the elderly: Mechanisms, challenges, and innovations.

Periodontology 2000·2026
Same author

An antifentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs.

The Journal of pharmacology and experimental therapeutics·2025
Same author

Long-term stability of transcrestal sinus augmentation.

Periodontology 2000·2025
Same author

Influence of 3D interrelationships on biological and prosthetic complications.

International journal of oral implantology (Berlin, Germany)·2025
Same journal

Semisynthesis of Mycothiazole Analogs having Distinct Bioactivity.

ACS medicinal chemistry letters·2026
Same journal

Investigation on the Cytotoxicity of Hydroxycinnamic and Hydroxybenzoic Acid-Based Natural Antioxidant Conjugated Terpyridine Analogues toward Triple-Negative Breast Cancer.

ACS medicinal chemistry letters·2026
Same journal

Beyond Neddylation Inhibition: X‑ray Structures Reveal Carbonic Anhydrase Isoform Selectivity of Pevonedistat.

ACS medicinal chemistry letters·2026
Same journal

Structure-Guided Discovery of Selective Polo-Like Kinase 3 Inhibitors.

ACS medicinal chemistry letters·2026
Same journal

Controlling Neuroplasticity Across Scales: Constrained Serotonergic Agonists, Neuroplastogens, and Adaptive Neuromodulation.

ACS medicinal chemistry letters·2026
Same journal

Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer.

ACS medicinal chemistry letters·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

14.6K

Truncated Orexin Peptides: Structure-Activity Relationship Studies.

Nadezhda A German1, Ann M Decker1, Brian P Gilmour1

  • 1Research Triangle Institute, Research Triangle Park, NC 27709.

ACS Medicinal Chemistry Letters
|April 8, 2014
PubMed
Summary
This summary is machine-generated.

Researchers identified OXA (17-33) as the shortest active orexin peptide, showing high selectivity for the OX1 receptor. Key amino acids like Tyr17 and Leu20 are crucial for its function in regulating energy and sleep.

Keywords:
OrexinPeptideStructure-activity relationship

More Related Videos

Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography
18:45

Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography

Published on: September 2, 2012

27.5K
Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method
10:53

Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method

Published on: February 26, 2018

50.0K

Related Experiment Videos

Last Updated: May 1, 2026

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

14.6K
Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography
18:45

Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography

Published on: September 2, 2012

27.5K
Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method
10:53

Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method

Published on: February 26, 2018

50.0K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Orexin receptors regulate critical physiological processes such as energy homeostasis, sleep-wake cycles, metabolism, and reward pathways.
  • Developing selective ligands for orexin receptors is crucial for elucidating their underlying mechanisms of action.

Purpose of the Study:

  • To investigate structure-activity relationships of orexin peptides.
  • To identify truncated forms of orexin peptides with activity at the OX1 receptor.
  • To determine the minimal sequence and key residues responsible for OX1 receptor agonism and selectivity.

Main Methods:

  • Peptide truncation studies were performed to identify the shortest active sequence.
  • Structure-activity relationship analyses, including alanine, D-amino acid, and proline scans, were conducted.
  • Selectivity assays were used to compare activity at OX1 versus OX2 receptors.

Main Results:

  • OXA (17-33) was identified as the shortest active peptide fragment, exhibiting 23-fold selectivity for OX1 over OX2 receptors.
  • Specific amino acid residues, including Tyr17, Leu20, Asn25, and His26, were found to be critical for the agonist properties of OXA(17-33).
  • The C-terminal conformation of orexin peptides appears to influence agonist activity and OX1 receptor selectivity.

Conclusions:

  • The truncated peptide OXA (17-33) represents a potent and selective OX1 receptor agonist.
  • Key residues and C-terminal conformation are essential determinants of orexin peptide activity and selectivity at the OX1 receptor.
  • These findings provide valuable insights for the design of novel orexin receptor-targeting therapeutics.